CN106137482A - A kind of nasal sinuses support and induction system - Google Patents
A kind of nasal sinuses support and induction system Download PDFInfo
- Publication number
- CN106137482A CN106137482A CN201510208438.3A CN201510208438A CN106137482A CN 106137482 A CN106137482 A CN 106137482A CN 201510208438 A CN201510208438 A CN 201510208438A CN 106137482 A CN106137482 A CN 106137482A
- Authority
- CN
- China
- Prior art keywords
- support
- nasal sinuses
- nasal
- support bar
- sleeve pipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a kind of nasal sinuses support, extend and be mounted with medicine, the support bar of straight tube-like structure along the longitudinal axis, this support bar has top and free end, and this support bar is provided with the clamping structure projected radially outwardly on the tube wall close on free end；And it is sheathed on the sleeve pipe on this support bar outer wall, this sleeve pipe has connection end and the movable end of annular, being provided with the many connection spokes arranged that are spaced apart from each other between this connection end and movable end, described top is connected the fixing connection of end with described, and described movable end can be equipped in described clamping structure.The present invention also provides for a kind of induction system.The nasal sinuses support of the present invention realizes conveying in a contracted state, and is supported in diseased region in the deployed state, and utilizes medicine to treat.
Description
Technical field
The present invention relates to a kind of extensible support, relate more specifically to a kind of nasal sinuses support and delivery system
System.
Background technology
Nasal sinuses is the sclerotin chamber of multiple gassiness around nasal cavity, and they all communicate with nasal cavity with tubule.Normal person
Nasal cavity and nasal sinuses in epidermal mucosa cell persistently have limpid liquid secretion out, thinner via mucosa
Cilium above born of the same parents has the pulsation of rule rate, by these secretions from nasal sinuses, flow to nasopharynx via nasal cavity backward
Chamber, throat are swallowed in esophagus and stomach again.General adult about secretes the mucus of 1 liter every day, by
These mucus maintain the humidity within nasal cavity and nasal sinuses, the simultaneously dust in absorption air and foreign body, with
The health of protection respiratory tract.Once because virus, the invasion of antibacterial, or the stimulation of foreign body, cause limpid
Mucilage secretion to become pus thick, or the pulsation having rule rate lost by cilium, all can produce the thick nasal mucus of pus or nose
The sensation that tears flow backwards, and cause rhinitis or nose film swelling, all can make these tubular occultation.When these tubules
Time inaccessible, just influence whether that nasal cavity mucus remains in a standstill in nasal sinuses, impact discharge.If diagnosis and treatment the most early,
Will develop and become sinusitis, allergic rhinitis or other rhinitis, there is nasal polyp in severe patient.
Nasal polyp bilateral is multiple, unilateral less.Common symptom is that persistence nasal obstruction is grown up with polyp volume
And increase the weight of.Nasal secretion increases, time with sneeze, secretions can be serosity, mucus, as also
Sending out sinus infection, secretions can be purulence.There is olfactory disorder more.Nasal obstruction severe one is spoken in closed rhinolalia,
Snore during sleep.Polyp base of a fruit elder can feel that nasal cavity has thing mobile with breathing.Choanal polyp can cause to exhale
Per nasal expiratory dyspnea during gas, if polyp blocks eustachian orifice, can cause tinnitus and auditory dysesthesia.Polyp hinders
Plug nasal sinuses drain, can cause serious sinusitis, and patient occurs that bridge of the nose, forehead and Face and cheek distending pain are uncomfortable.
Nasal polyp visible nasal cavity when rhinoscopy has one or more smooth surface, canescence, yellowish
Color or pink swollen thing as translucent in Fructus Litchi meat-like.The softness touched, the most bitterly, is difficult to hemorrhage, nothing in it
Liquid, but loose connective tissue, color is dark red or pale, with normal mucosa without obvious border, sternly
Severe disease example in addition to concha nasalis inferior almost without normal mucosa；CT examination is shown and is entirely organized sinusitis, majority of cases middle nasal concha
Gas room disappears, and concha nasalis inferior is raised.MRI shows sinus mucosa centration edema, and signal is uniform；Rotary-cut is performed the operation
After quickly recur.The little person of polyp must shrink concha nasalis with vasoconstrictor or could find with nasal endoscopes.Polyp
Big and many person, advances and can dash forward to prenaris, its front end because often being stimulated by outside air and dust, in
Pale red, there are ulcer and crust in surface sometimes.Nasal polyp develops backward can dash forward to choana even nasopharynx.
Huge nasal polyp can cause external nose to deform, and bridge of the nose broadens, and is formed " frog nose ".The visible thin slurry of nasal cavity
Fluidity or sticky, purulent secretion.
Current polypous Therapeutic Method has the sides such as traditional nasal-cavity administration, functional endoscopic sinus surgery
Method.
Nasal-cavity administration refers to that medicine uses at nasal cavity, topically or systemically controls by stimulating nasal mucosa to play
Treatment effect, thus reach a kind of outer treating method prevented and cured diseases.Nasal-cavity administration is traditional to prescription as one
Formula is long-standing, extremely wide in department of otorhinolaryngology application, is generally used to treat various nasal cavity and disease of nasal sinus,
Also can be as adjuvant drug for the adjacent organs illness relevant with cacorhinia, in the process that the mankind prevent and cure diseases
In the middle of played an important role.But due to the stop of intranasal tissue, active drug can not reach smoothly
To diseased region, do not reach therapeutic purposes.
Functional endoscopic sinus surgery, by by the good illumination of endoscope and supporting operating theater instruments,
Operation can be made to become finer.By traditional radical-ability or the destructiveness of mucosa in all striking off nasal sinuses
Operation, is changed on the basis of thoroughly removing pathological changes, retains nasal cavity and the normal mucosa of nasal sinuses as far as possible
And structure, form good ventilation and drain, promote nasal cavity, the form of sinus mucosa and physiological function extensive
Multiple Functional operation.And can reach to rely on nasal cavity and nasal sinuses self raw according to the order of severity of pathological changes
Rhinitis, sinusitis and polypous purpose are cured in the recovery of reason function.Owing to its light conductivity is strong, polygonal
Degree, the visual field are big, can directly spy on nasal cavity many significant points (such as each nasal sinuses opening, each
Hidden stenosis within ditch, nasal sinuses) and the small lesions of nasopharynx part.Except operative treatment, also can be same
Shi Jinhang images, and preserves data, sums up for the consultation of doctors, teaching demonstration and scientific research.The method has wound
In little, art and the advantage such as postoperative misery is little, operation is fine, but expensive, the shortcomings such as relapse rate is high.
Excision polyp, Postoperative recurrent rate is 30%～50%, average each patient will row 1.5～4 times operation,
The most.And such as nose is often excised in the treatment operation of excision and change nose and nasal sinuses
First, nasal septum, the anatomical structure of nasal membrane etc..This kind of excision and reconstructive operation can destroy to be tied by these
What structure was provided naturally filters and humidification, causes being dried, hemorrhage, and incrustation adds the risk of infection,
And cause olfactory sensation to change, including hyposmia, olfactory disorder, parosmia and anosmia.
Summary of the invention
In order to solve the problem that above-mentioned prior art exists, it is desirable to provide one can be accurate by medicine
The diseased region delivering to nasal cavity the nasal sinuses support directly acting on this and the induction system of medicine.
The present invention provides a kind of nasal sinuses support, and this nasal sinuses support extends along the longitudinal axis and is mounted with medicine, directly
The support bar of tubular structure, this support bar has top and free end, and this support bar is closing on free end
Tube wall is provided with the clamping structure projected radially outwardly；And it is sheathed on the sleeve pipe on this support bar outer wall,
This sleeve pipe have annular connection end and movable end, be provided with between this connection end and movable end many that
The connection spoke being spaced apart around here, described top is connected the fixing connection of end with described, and described movable end can
It is equipped in described clamping structure.
Described sleeve pipe also includes the many free spokes extended from described connection end.
Described connection spoke and described free spoke are alternately arranged.
Described connection spoke is uniformly distributed along the circumference of described sleeve pipe.
Described clamping structure is the tongue piece projected radially outwardly of thermal finalization.
Described clamping structure is uniformly distributed along the circumference of described support bar.
The present invention also provides for a kind of induction system, and this induction system includes connecting rod and push rod, wherein, institute
State connecting rod to be connected on above-mentioned nasal sinuses support, and pushing rod sleeve is located in described connecting rod.
Described connecting rod is straight tube-like structure, has identical diameter with described support bar.
Described push rod is the circular tube structure of both ends open, and the internal diameter of described push rod is more than outside described connecting rod
Footpath, the external diameter of described push rod is less than the internal diameter of described sleeve pipe.
The nasal sinuses support of the present invention utilizes the support force of sleeve pipe, it is possible to blocking nasal cavity cyst shape polyp with
Physical support mode squeezes, and utilizes the medicine loaded on this nasal sinuses support while keeping nasal airflow
Directly act on diseased region, the slow release of long period can be realized the most as required, thus right
Lesion locations gives sustained drug treatment.The nasal sinuses support of the present invention realizes conveying in a contracted state, and
Act on diseased region in the deployed state, the nasal cavity of nasal polyp blocking is played a supportive role, maintains nose
The permeability in chamber, in like manner utilization is carried on the medicine on nasal sinuses support and effectively controls nasal polyp affected part
Treat.
Accompanying drawing explanation
Fig. 1 is the schematic perspective view that the nasal sinuses support according to the first embodiment of the present invention is in deployed condition；
Fig. 2 is the schematic perspective view that the nasal sinuses support according to the first embodiment of the present invention is in contraction state；
Fig. 3 is the schematic perspective view of the support bar of the nasal sinuses support according to the first embodiment of the present invention；
Fig. 4 is the enlarged drawing of the region A in Fig. 3；
Fig. 5 is the solid that the sleeve pipe of the nasal sinuses support according to the first embodiment of the present invention is in contraction state
Schematic diagram；
Fig. 6 is the enlarged drawing of the region B in Fig. 5；
Fig. 7 is the solid that the sleeve pipe of the nasal sinuses support according to the first embodiment of the present invention is in deployed condition
Schematic diagram；
Fig. 8 a is the solid that the sleeve pipe of nasal sinuses support according to the second embodiment of the present invention is in deployed condition
Schematic diagram；
Fig. 8 b is the solid that the sleeve pipe of nasal sinuses support according to the third embodiment of the invention is in deployed condition
Schematic diagram；
Fig. 9 is the schematic perspective view of the induction system according to the first embodiment of the present invention；
Figure 10 is according to the connection on the nasal sinuses support being connected to contraction state of the first embodiment of the present invention
The schematic perspective view of bar；
Figure 11 is according to the connection on the nasal sinuses support being connected to deployed condition of the first embodiment of the present invention
The schematic perspective view of bar；
Figure 12 is the schematic perspective view of the push rod according to the first embodiment of the present invention；
Detailed description of the invention
Below in conjunction with the accompanying drawings, provide presently preferred embodiments of the present invention, and be described in detail.
Fig. 1-Fig. 2 shows the nasal sinuses support 1 according to the first embodiment of the present invention, this nasal sinuses support 1
There is during expansion lantern-shaped profile as shown in Figure 1, there is during contraction cylindrical outer shape as shown in Figure 2.
There are a support bar 11 extended along longitudinal axis L and the sleeve pipe 12 being sheathed on this support bar 11 outer wall in its center,
Both are at one end fixing connects.
The structure of support bar 11 is as it is shown on figure 3, this support bar 11 is straight tube-like structure, and one end is and set
The top 111 that pipe 12 is affixed, the other end is free end 112.On the tube wall closing on free end 112, if
There is the clamping structure 113 projected radially outwardly.As shown in Figure 4, this clamping structure 113 is in the present embodiment
For being formed at the tongue piece on support bar tube wall.I.e. it is respectively cut wall (phase in tube wall both sides diametrically
The otch answered is 1131) form the tongue piece 1132 being connected on one side with tube wall, this tongue piece 1132 passes through the hottest
Process processes to be fixed to project radially outwardly.When having radially inner External Force Acting in this tongue piece 1132
Time upper, this tongue piece 1132 radially-inwardly shrinks and close incisions 1131 with connecting portion 1133 for rotating shaft, from
And recover tubular structure.Generally, the external diameter of this support bar 11 is 3mm-5mm, and wall thickness is
0.2mm-0.5mm, and the axial length of support bar 11 is 10mm-30mm.Clamping structure 113 is along propping up
The circumference of strut 11 is uniformly distributed, and its quantity can be 2,3,4,5 or 6, preferably
For 2-3.
As shown in Figure 5-Figure 7, the two ends of this sleeve pipe 12 are respectively the connection end of annular to the structure of sleeve pipe 12
121 and movable end 122, be that circumferentially uniform intervals is arranged connecting between end 121 and movable end 122
Connection spoke 123.This connection spoke 123 is by between connecting between end 121 and movable end 122 uniformly
Formed every cutting tube wall, make, between connection spoke 123 adjacent one another are, there is gap.Thus so that
Sleeve pipe 12 is tubular structure as shown in Figure 5 when not stressing, and in the case of by External Force Acting,
Connect spoke 123 then radial outward dilations, form lantern-shaped structure as shown in Figure 7.Generally, sleeve pipe
The wall thickness of 12 is 0.2mm-2mm, and the quantity connecting spoke 123 can be 3-10 root, connects spoke 123
Width be 1mm-2mm, a length of 25mm-50mm.Preferably, this sleeve pipe 12 can be by thin-wall pipes
Formed through rapid laser carving.
Returning to Fig. 1-Fig. 2, connection is fixed with being connected end 121 in top 111, such as, can be to cohere with glue
Together, it is also possible to be welded to together, make between the two without relative motion.As shown in Figure 1
Deployed condition, movable end 122 is equipped on the tongue piece 1132 of support bar 11, now, connect spoke
123 are all radially furthered out and make sleeve pipe 12 have the profile of major diameter, and diameter now reaches
8mm-25mm.At contraction state as shown in Figure 2, it is internal that free end 112 is placed in sleeve pipe 12, and
The tongue piece 1132 of support bar 11 in the circumferential in the adjacent gap connected between spoke 123, this
Time, connect spoke 123 and be in nature overhang and make sleeve pipe 12 have the profile of minor diameter,
Diameter now is about at 3mm-5mm.
Fig. 8 a gives the sleeve pipe of nasal sinuses support according to the second embodiment of the present invention and is in deployed condition
Schematic perspective view, the two ends of this sleeve pipe 12a are respectively the connection end 121a and movable end 122a of annular,
Connect between end 121a and movable end 122a is the connection spoke 123a that circumferentially uniform intervals is arranged.
This connection spoke 123a is by uniform intervals cutting tube wall between connection end 121a and movable end 122a
Formed, make, between connection spoke 123a adjacent one another are, there is gap.Many are also extended from connecting end 121a
Free spoke 124a, free spoke 124a are arranged in the gap between adjacent connection spoke 123a,
I.e. connect spoke 123a and free spoke 124a alternately arranged.Generally, the wall thickness of sleeve pipe 12a is
0.2mm-2mm, the quantity connecting spoke 123a and free spoke 124a can be 3-10 root respectively, even
The width meeting spoke 123a and free spoke 124a is 1mm-2mm, connects the length of spoke 123a
For 25mm-50mm, and the length of free spoke 124a is longer than the length connecting spoke 123a
3mm-10mm.Under real use state, free spoke 124a's can away from the tail end connecting end 121a
It is in middle nasal concha and septonasal opening part, owing to the hole of middle nasal concha and septonasal opening part is more than living
The external diameter of moved end 122a, this flared tail end is more conducive to the outflow of nose liquid, and has middle nasal concha more
Strong supporting role.
Fig. 8 b gives the sleeve pipe of nasal sinuses support according to the third embodiment of the invention and is in deployed condition
Schematic perspective view, the two ends of this sleeve pipe 12b are respectively the connection end 121b and movable end 122b of annular,
Connect between end 121b and movable end 122b is the connection spoke 123b that circumferentially uniform intervals is arranged.
This connection spoke 123b is by uniform intervals cutting tube wall between connection end 121b and movable end 122b
Formed, make, between connection spoke 123b adjacent one another are, there is gap.Also extend many from connecting end 121b
Root free spoke 124b, free spoke 124b are arranged in the gap between adjacent connection spoke 123b,
An a piece free spoke 124b and connection spoke 123b is as one group, the most seamless, tightly
Get together.I.e. connect spoke 123b and free spoke 124b alternately arranged.Generally, sleeve pipe 12b
Wall thickness is 0.2mm-2mm, and the quantity connecting spoke 123b and free spoke 124b can be 3-10 respectively
Root, the width connecting spoke 123b and free spoke 124b is 1mm-2mm, connects spoke 123b
A length of 25mm-50mm, and the length of free spoke 124b than connect spoke 123b length long
3mm-10mm.It addition, a series of fan groove 125b, fan groove 125b are carved with in the top connecting end 121b
Being distributed uniformly and circumferentially, radian is generally 5 °-20 °, and the degree of depth is 0.5mm-3mm.When support exhibition
After opening, spoke bar upper end by pulling force radially, and can connect end 121b near the place connecting end 121b
Upper end due to the existence of fan groove 125b, can be connected end 121b upper end diameter meeting by pressure radially
Diminish, and lower end can become big.Up-small and down-big shape is presented so that free spoke owing to connecting end 121b
124b has the trend expanded outwardly, and which enhances the support force of free spoke 124b lower end.
Fig. 9 shows the induction system according to the first embodiment of the present invention, for being in contraction state
Nasal sinuses stent expansion be the nasal sinuses support being in deployed condition, this induction system includes connecting rod 2 and pushes away
Bar 3, wherein, connecting rod 2 is connected on nasal sinuses support 1, and push rod 3 is sheathed in connecting rod 2.
Figure 10 shows that connecting rod 2 is connected on the nasal sinuses support 1 of contraction state；And Figure 11 shows
Connecting rod 2 is connected on the nasal sinuses support 1 of deployed condition.As shown in Figure 11, this connecting rod 2 is straight tube
Shape structure, has identical diameter with support bar 11, and specifically, this connecting rod 2 is connected to support bar 11
Free end 112, it is preferable that this connecting rod 2 can be integrally formed with support bar 11, needs remove
Wiping out of necessity is carried out the when of connecting rod 2.It should be understood that connecting rod 2 is passed through with support bar 11
It is also feasible that female thread connects.The axial length of this connecting rod 2 is 90mm-180mm.
Figure 12 shows the structure of push rod 3, and this push rod 3 is the circular tube structure of both ends open, dimensionally,
The internal diameter 0.01mm-0.1mm more bigger than the external diameter of connecting rod 2 of push rod 3, the external diameter of push rod 3 compares sleeve pipe
The smaller 0.01mm-0.1mm of internal diameter of 12.
In conjunction with Fig. 9-Figure 11, in concrete course of conveying, first, connecting rod 2 is connected to support bar
The free end 112 of 11, then by push rod 3 from the free end of connecting rod 2 towards the direction of nasal sinuses support 1
Being set in the outside of connecting rod 2, the position now keeping connecting rod 2 is motionless, continues to move to push rod 3, by
More smaller than the internal diameter of sleeve pipe 12 in the external diameter of push rod 3, the free end closing on nasal sinuses support 1 of push rod 3 will
Movable end 122 is promoted to move along the outer surface of support bar 11 towards connecting end 121, so that connect
Spoke 123 radial outward expansion, when movable end 122 arrives tongue piece 1132 position, this movable end
122 pairs of these tongue pieces 1132 apply radially inner external force, and this tongue piece radially-inwardly shrinks and is placed in otch
In 1131, movable end 122 continues to move, when movable end 122 fully passes over otch towards connection end 121
After 1131, such as, reverted to the shape projected radially outwardly by the tongue piece 1132 of Technology for Heating Processing processing sizing
State, the most outwards withdraws from push rod 3, and by tongue piece 1132 blocking, sleeve pipe 12 keeps launching shape movable end 122
State, as shown in figure 11.Finally, the connection between connecting rod 2 and support bar 11 is released.In reality
Under border use state, nasal cavity stayed by the nasal sinuses support 1 being in deployed condition, and cause nasal polyp is stifled
Plug is played a supporting role, so that nasal cavity is unobstructed.
In the present invention, nasal sinuses support can be formed by nondegradable material, and such as metal, at nasal polyp
After having treated, the support of this non-degradable material takes out from nasal cavity.Nasal sinuses support can also be by dropping
The material solved is formed, and such as degradable metal, or Biodegradable polymer material are controlled at nasal polyp
After treatment completes, the support of this degradation material can also take out from nasal cavity, is preferably and does not takes out, but
Nasal cavity is gradually degraded, ultimately produces water and carbon dioxide, or little molecule is discharged by nasal cavity.
Nasal sinuses support of the present invention can be by materials processings such as rustless steel, cochrome, Nitinols
Become, it is also possible to by degradable metal such as magnesium, pure iron etc. is formed.Particularly magnesium alloy, the most extensively quilt
It is applied to the field such as cardiovascular specialist, orthopaedics implant.Magnesium alloy has relatively low corrosion potential, is containing
Have under the internal milieu of chloride ion and easily corrode, and the most degradable in the way of slowly corrosion,
Its corrosion product is to organism nonhazardous effect, and participates in human homergy.
Nasal sinuses support of the present invention can also be made up of degradable high polymer material, and macromolecular material is not by
Same polymer or copolymer, or use different processing modes, as being blended, the shape such as hollow or interlayer
Formula regulates degradation speed, the demand different to adapt to the treatment cycle of different sufferer.
One or more in following material of this Biodegradable polymer material: degradable Polyurethane,
Degradable polyester, autohemagglutination (L-lactide-co-d-lactide), poly-(L-lactide-co-d, L-lactide),
Poly-(D-lactide-co-d, L-lactide), PLG, poly-(lactide-co-ε-
Caprolactone), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-6-caprolactone), poly-(lactide-co-two alkanone), poly-(second hand over
Ester-co-two alkanone), poly-(lactide-co-trimethylene carbonate), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-three methylene
Base carbonic ester), poly-(lactide-co-ethylene carbonate), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-ethylene carbonate), poly-(third
Lactide-co-Allyl carbonate), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-Allyl carbonate), poly-(lactide-co-2-methyl-2-
Carboxyl-Allyl carbonate), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-2-methyl-2-carboxyl-Allyl carbonate), poly-(3-hydroxyl
Butyrate-co-4 hydroxybutyric acid ester), poly-(butyric ester-co-hydroxyl valerate), poly-(3-hydroxyl fourth
Acid esters-co-3-hydroxyl valerate), poly-(4 hydroxybutyric acid ester-co-3-hydroxyl valerate), poly-(ε-oneself in
Ester-co-fumarate), poly-(6-caprolactone-co-fumaric acid propylene glycol ester), poly-(lactide-co-second two
Alcohol), poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-ethylene glycol), poly-(6-caprolactone-co-ethylene glycol), poly-(DETOSU-1,6-HD-
Co-DETOSU-t-CDM), poly-(lactide-co-glycolide-co-6-caprolactone), poly-(lactide-co
-Acetic acid, hydroxy-, bimol. cyclic ester-co-trimethylene carbonate), poly-(lactide-co-6-caprolactone-co-trimethylene carbonate),
Poly-(Acetic acid, hydroxy-, bimol. cyclic ester-co-6-caprolactone-co-trimethylene carbonate) and poly-(3-hydroxybutyrate ester-co-3-hydroxyl
Base valerate-co-4 hydroxybutyric acid ester), lactide therein includes L-lactide, D-lactide and D, L-
Lactide.PVP, PVA, starch, biomolecule (such as fibrin, Fibrinogen, cellulose,
Collagen protein and hyaluronic acid), polyurethane, artificial silk, artificial silk Triafol T, cellulose, second
Acid, cellulose butyrate, acetylbutyrylcellulose, cellophane, celluloid, cellulose propionate, fine
Dimension element, and carboxymethyl cellulose.
Especially, this Biodegradable polymer material is that PLA and PGA (or PCL) is blended or copolymerization
Polymeric material, it might even be possible to be two kinds of copolymers be blended.On the one hand, this base polymer is the widest
It is applied to the three class medical device product such as intravascular stent, stitching thread, orthopaedics implant for many years generally, has
More preferable biocompatibility, it is to avoid the generation of some complication caused by material.It addition, according to facing
Bed practical situation, has carried out arranging to reach the good collocation of support force and degradation cycle to the proportioning of material.
Wherein, PLA is blended or mass percent shared in the polymeric material of copolymerization can at PGA and PLA
Think 0%-85%, preferably 5-50%；PCL is shared in the polymeric material that PLA and PCL is blended
Mass percent can be 0-50%, preferably 5-30%.More further, they can be two kinds of copolymerization
Being blended of thing, such as: 1090PLGA with 8515PLGA is blended, 1090PLGA and 9010PLGA
Being blended, 8515PLGA Yu 5050PLGA is blended, 1090PLGA Yu 7030PLC is blended, etc.,
So can be used to produce the nasal sinuses support of different degradation time, meet the requirement of different support strength, portion
Dividing product requirement support strength is about 1-3 month, can pass through the regulation of copolymerization proportioning, or blending ratio
Regulation meets requirement.
Can polymer blend in addition to above-mentioned degradable polymer, also include synthesis and natural hydrolytic degradation
Polymer.Synthesis hydrolyzes biodegradable polymer can include that hydrolytic degradation polyester includes poly-(L-
Lactic acid-ethanol) (PLGA).Typical natural biodegradable polymer includes chitosan.Typical case
Water-soluble polymer include PEG (PEG), PEG block polymer, PEG/PLA with
PEG polymer, PEG is random or alternate copolymer, such as Polyethylene Glycol/PLGA copolymer, sucrose, forms sediment
Powder, Algin, polyvinylpyrrolidone (PVP), and poly-(vinyl alcohol) (PVA).Poly-(N-acetyl
Glycosamine) (chitin), poly-(ester), poly-(3-hydroxybutyrate ester), poly-(4 hydroxybutyric acid ester), poly-
(hydroxybutyric acid-hydroxypentanoic acid), poly-(DL-lactide-co-caprolactone), poly-(Acetic acid, hydroxy-, bimol. cyclic ester ε altogether-own interior
Ester), PTMC, polyesteramide, poly-(glycolic-trimethylene carbonate), poly-(ether
-ester) (such as, PEO/ polylactic acid), polyphosphazene etc..
Degradable polymer even can be blended with magnesium alloy, increases initial strength, but accelerates later stage degradation.
Nasal sinuses support of the present invention is mounted with medicine, effectively can treat nasal polyp affected part, and
And slow release can be realized as required.
The outer surface of nasal sinuses support of the present invention is loaded with medicine.After nasal sinuses stenter to implant, outside support
The medicine on surface starts to discharge to the nasal wall contacted and polyp, it is suppressed that polypous regrowth,
Decrease the inflammation of nasal cavity.
The release of medicine is adjusted according to the polypous order of severity, i.e. nasal polyp hypertrophy is very serious, then
Can increase the dosage of medicine, extending the deenergized period of medicine, such as drug release can be 7 days-3 simultaneously
Release in individual month is complete, it is also possible to extend to 6 months-1 years, simultaneously constitutes the material fall of nasal sinuses support
Solve characteristic also the most consistent with drug release.Simultaneously nasal sinuses rack surface can also be coated with two kinds or
Several different medicines, several drugs layered coated, release order press layer discharge, when the top, medicine is released
After putting, below medicine be further continued for release.
Medicine can be selected but be not limited only to medicine set forth below: long-acting steroids hormone, anti-inflammatory drug,
Anti-allergic drug, parasympatholytic, antihistaminic medicine, anti-infective, antiplatelet drug,
Anticoagulation, antithrombotic, anti-cicatrix medicine, antiproliferative pharmaceutical, chemotherapeutic, antineoplastic agent, solution hyperemia agent,
Accelerator for concrescence, vitamin (such as: tretinoin, vitamin A, vitamin B, and spin-off), exempt from
Epidemic disease modulating agent, immunosuppressant, and the compositions of above-mentioned medicament or mixture.
Optional infection medicament generally include antibacterial, antifungal, antiparasitic, antiviral agent,
Preservative.Anti-inflammatory agents generally includes steroid or nonsteroid anti-inflammatory drugs.
The antiallergic medicament that may be used for the present invention includes but are not limited to: Pemirolast Potassiu
(Santen, Inc.), cetirizine hydrochloride, levo-cetirizine hydrochloride, and any medicine
Thing precursor, metabolite, derivant, homologue, congener, derivatives, salt, and their compositions.
The medicament of anti-malignant cell proliferation includes but are not limited to, actinomycin D, D actinomycin D IV, actinomycetes
Element I1, D actinomycin D X1, Dactinomycin, dactinomycin (Merck&Co.,
Inc.).Antiplatelet drug, anticoagulant, antifibrin and antithrombase include but are not limited to, liver
Element sodium, low molecular weight heparin, heparinoid, hirudin, argatroban, Forskolin, vapiprost,
Ring prostatitis element, class ring prostatitis element, glucosan, D-Phe-Pro-arginine-chloromethane keto hydrochloride
(chemosynthesis antithrombase), dipyridamole, glycoprotein I I b/III a platelet membrane receptor antagonist resist
Body, lepirudin 023 ludon, thrombin inhibitor (Biogen, Inc.), and any medicine
Precursor, metabolite, derivant, homologue, congener, derivatives, salt and their compositions.
The cytostatics and the anti-cell proliferation that may be used for the present invention include but are not limited to: angiopeptin；
Angiotensin converting enzyme inhibitor, as captopril (
Bristol-Myers Squibb Co.), cilazapril, lisinopril (
Merck&Co.,Inc.)；Calcium channel blocker, such as nifedipine, colchicine；Fibroblastic growth
The factor (FGF) antagonist, cod-liver oil (omega-fatty acid)；Histamine antagonist；Lovastatin
(Merck&Co.,Inc.)；Monoclonal antibody, includes but are not limited to, platelet
Derivative growth factor (PDGF) receptor specific antibody；Sodium nitroprusside；Phosphodiesterase inhibitor；Prostatitis
Parathyrine inhibitor；Suramin；Serotonin blocker；Steroid；Sulfur is for protease inhibitor；Platelet
Derivative growth factor (PDGF) antagonist, includes but are not limited to, triazolo pyrimidine；Nitric oxide；
And any prodrug, metabolite, derivant, homologue, congener, derivatives, salt, and he
Compositions.
The antimicrobial agent that may be used for the present invention includes but are not limited to: aminoglycoside, amphenicols,
Ansamycins, beta-lactam antibiotic, such as penicillins, lincomycin class, Macrolide,
Itrofurans, quinolones class, sulfonamides, sulfone class, Tetracyclines, vancomycin, and
Their derivant and compositions.The type agents of the support that may be used for the application include but not only
Be limited to: Amdinocillin, pivmecillinam, amoxicillin, ampicillin, aspoxicillin,
Azidocillin, bacampicillin, benzyl penicillinic acid, penicillin sodium, carbenicillin, carindacillin, chloromethane
XiLin, cloxacillin, ciclacillin, dicloxacillin, epicillin, fenbenicillin, flucloxacillin,
Hetacillin, lenampicillin, metampicillin, Staphcillin sodium, mezlocillin, sodium nafcillin,
Oxazacillin, penamecillin, penethacillin hydriodate, benethamine penicillin, benzathine penicillin G, green grass or young crops
Mycin G .alpha.-aminodiphenylmethane. salt, calcium benzylpenicillinate, hydrabamine penicillin G, scotcil, procaine
Benzylpenicillin, penicillin N, penicillin, penicillin V, penicillin V benzathine, Hydrabeamine Penicillin
That west of V, penimepicycline, penicillin-152, piperacillin, pivampicillin, propicillin, quinoline
Woods, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin.
The antifungal medicine that may be used for the present invention includes but are not limited to: propylamine, imidazoles, many
Alkenes, Thiocarbamates, triazole type, and derivative medicament.Antiparasitic include but not only
Be limited to, atovaquone, clindamycin, dapsone, double electricity quinoline, metronidazole, pentamidine, primaquine,
Pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole, trimetrexate and mixture thereof.
The antiviral agent that may be used for the present invention includes but are not limited to: acyclovir, famciclovir,
Valacyclovir, edoxudine, ganciclovir, FOSCARNET, cidofovir, Fomivirsen, HPMPA (9-
(3-hydroxyl-2-phosphate methoxy propyl group)-adenine), PMEA (9-(2-phosphate methoxy propyl group)-
Adenine), HPMPG (9-(3-hydroxyl-2-phosphate methoxy propyl group)-guanine), PMEG (9-[2-
Phosphate methoxy propyl group] guanine), HPMPC (1-(2-phosphate methoxy-3-hydroxypropyl)-cytosine),
Ribavirin, EICAR (5-acetenyl-1-β-D-RIBOSE base-1H-imidazoles-4-Methanamide), pyrazoles
Furan rhzomorph (3-[β-D-RIBOSE]-4-hydroxypyrazoles-5-Methanamide), 3-look into Chinese holly woods,
GR-92938X (1-β-D-RIBOSE base-1H-pyrazoles-3,4-diformamide), LY253963 (1,3,4-
Thiadiazoles-2-base-cyanamide), RD3-0028 (1,4-dihydro-2,3-benzyl two sulfur), CL387626 (4,4'-bis-
[4,6-d] [3-aminobenzene-N, N-bis-(2-carbamoylethyl)-sulfonic acid acid imide]-1,3,5-triazine-2-base amino
-biphenyl-2-, 2'-sodium disulfonate), BABIM (two [5-amidino groups-2-benzimidazole-l]-methane) NIH351,
And mixture.
The Cidex-7 agent that may be used for the present invention includes but are not limited to: ethanol, hibitane, iodine tincture,
Triclosan, hexachlorophene and silver-based agents: such as silver chloride, silver oxide, nano-Ag particles.
The antiinflammatory class medicament that may be used for the present invention includes steroid and nonsteroidal anti-inflammatory agent.Suitable
Steroidal anti-inflammatory drug thing include but are not limited to, 21-acetyl oxygen pregnenolone, alclometasone, Ah
Your progesterone, amcinonide, beclometasone, betamethasone, budesonide, chloroprednisone, clobetasol,
Clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort,
(11BETA,16ALPHA)-16,17-[methylethylidenebis(oxy), desoximetasone, dexamethasone, diflorasone, diflucortolone, two fuprednate butyl esters, sweet
Grass subacid, Fluazacort, flucloronide, flumetasone, good fortune Buddhist nun shrinkage porosite, fluocinonide, fluocinonide,
Novoderm Varlane, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, good fortune prednisolone, fluorine
Hydrogen shrinkage porosite, fluticasone propionate, formocortal, halcinonide, Halobetasol Propionate, halometasone,
Halopredone acetate, hydrocortamate, hydrocortisone, Loteprednol etabonate, depersolon, first hydroxyl
Pine, meprednisone, methyl meticortelone, Mo Meitasong furoate, paramethasone, prednicarbate, sprinkle
Ni Songlong, 25-diethylin prednisolone acetate, Inflamase, prednisone, prednisolone penta
Acid esters, ripple prednylidene 21-diethylaminoacetatte, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide,
Triamcinolone, triamcinolone hexacetonide, and derivant and compositions.
The nonsteroidal anti-inflammatory agent that may be used for the present invention includes but are not limited to, epoxidase (cox)
Inhibitor.This kind of epoxidase (cox) inhibitor potentially includes COX-1 or COX nonspecific inhibitor,
Such as, salicyclic acid derivatives, aspirin, sodium salicylate, Choline magnesium trisalicylate, salsalate,
Diflunisal, sulfasalazine, olsalazine；P-aminophenol derivatives, such as, to acetyl ammonia
Base phenol；Indole and indeneacetic acid, such as, indomethacin and sulindac；Iso-aryl acetic acid class, such as, first
Benzoyl pyridylacetic acid, diclofenac, ketorolac；Arylprop acids, such as, ibuprofen, naproxen,
Flurbiprofen, ketone ibuprofen, Fino ibuprofen, oxaprozin；Anthranilic acid (that acid fragrant),
Such as, mefenamic acid, meloxicam；Enol acid, such as, former times health class (piroxicam, U.S. Lip river former times
Health)；Aldoketones, such as, nabumetone.COX inhibitor may also include selectivity cyclooxygenase COX2,
Such as, diaryl substituted furan ketone, rofecoxib；Diaryl substituted pyrazole class, celecoxib；Yin
Indolylbutyric acid class, e.g., etodolac；Sulfonamides, e.g., nimesulide.
The chemotherapy and the anti-tumor agents that may be used for the present invention include but are not limited to: anticancer agent is (e.g.,
Chemotherapy of tumors medicine, biological response modifiers, angiogenesis inhibitor, hormone receptor blocker, low temperature are controlled
Treat reagent and other can destroy or suppress tumor generate and growth medicament), such as, alkylating agent or
Other can be attacked by DNA directly kill cancerous cell medicament (e.g., cycli phosphate amine, isoendoxan),
Nitroso ureas or other kill medicament (e.g., the carmustine of cancerous cell by suppression cell DNA reparation
(BCNU), lomustine (CCNU)), antimetabolite or other by interference specific cells function hinder
The only medicament of growth of cancer cells, usually DNA synthesis (e.g., 6-mercaptopurine, 5 fluorodioxy pyridines (5FU),
Antitumor antibiotics and other can retrain or arrange DNA and go forward side by side the compound once stoping DNA to synthesize
(e.g., amycin, daunomycin, epirubicin, idarubicin, Mitomycin-C, bleomycin A5),
Plant (Herba Catharanthi Rosei) alkaloid and other by anti-tumor agent comprising salmosin (e.g., vincristine, the length of plant extract
Spring flower alkali), steroid hormone, hormone inhibitors, hormone receptor antagonists and other to affect hormone anti-
(e.g., tamoxifen, Trastuzumab, arimedex, e.g., amino is different to answer the medicament of growth of cancers
Sleeping can be with Formestane, triazole inhibitor, e.g., and letrozole and Anastrozole, steroid inhibitor, e.g.,
Exemestane), anti-angiogenesis albumen, little molecule, gene therapy and (or) other can suppress
Neonate tumour blood vessel or angiopoietic medicament (e.g., meth-1, meth-2, Sa Li polyamines), shellfish cut down list
Anti-(Avastin), fish shark amine, endostatin, angiostatin, Angiozyme, AE-941 (cancer
Vertical disappear), CC-5013 (Revimid, a kind of thalidomide derivatives), medi-522 (Vitaxin), 2-
Methoxyestradiol (2ME2, Panzem), CAI (CAI), Kang Purui fourth A4 medicine precursor (CA4P),
SU6668、SU11248、BMS-275291、COL-3、EMD 121974、IMC-1C11,IM862、
TNP-470, celecoxib (celecoxib Celebrex), rofecoxib (Vioxx Vioxx), interferon
α, interleukin 12 (IL-12) or any at Science Vol.289,1197-1201 page (Aug.17,2000)
Identified compound, these compounds are all incorporated herein by reference.Biological effect regulation reagent is (e.g.,
Interferon, bacill calmette-guerin (BCG), monoclonal antibody, interleukin-22, granulocyte colony-stimulating factor (GCSF)
Deng), PGDF receptor antagonist, Trastuzumab, asparaginase, busulfan, carboplatin, cisplatin, card not
Department spit of fland, chlorambucil, cytosine arabinoside, dacarbazine, etoposide, flucarbazonesodium, fluorouracil,
Gemcitabine, hydroxyurea, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine,
Methotrexate, thioguanine, phosphinothioylidynetrisaziridine, Raltitrexed, topotecan, bent fourth sulphur ester, vincaleucoblastine,
Vincristine, mitoazitrone, oxaliplatin, procarbazine, streptostacin, paclitaxel, many west he
Match, imuran, docetaxel derivant homologue, derivatives of these compounds and combinations thereof thing.
Above-described, only presently preferred embodiments of the present invention, it is not limited to the scope of the present invention,
The above embodiment of the present invention can also make a variety of changes.The most every right according to the present patent application is wanted
Ask change simple, equivalent and modification that book and description made, fall within the right of patent of the present invention
Claimed scope.The most detailed description of the present invention be routine techniques content.
Claims (10)
1. a nasal sinuses support, it is characterised in that this nasal sinuses support extends along the longitudinal axis and is mounted with medicine,
Comprising:
The support bar of straight tube-like structure, this support bar has top and free end, and this support bar is closing on certainly
The clamping structure projected radially outwardly it is provided with by the tube wall held；And
Being sheathed on the sleeve pipe on this support bar outer wall, this sleeve pipe has connection end and the movable end of annular,
Be provided with between this connection end and movable end many be spaced apart from each other arrange connection spokes, described top with
Described connection end is fixing to be connected, and described movable end can be equipped in described clamping structure.
Nasal sinuses support the most according to claim 1, it is characterised in that described sleeve pipe also includes from institute
State and connect the many free spokes that end extends.
Nasal sinuses support the most according to claim 2, it is characterised in that described connection spoke and described
Free spoke is alternately arranged.
Nasal sinuses support the most according to claim 1, it is characterised in that described connection spoke is along institute
The circumference stating sleeve pipe is uniformly distributed.
Nasal sinuses support the most according to claim 1, it is characterised in that described clamping structure is that heat is fixed
The tongue piece projected radially outwardly of type.
Nasal sinuses support the most according to claim 1, it is characterised in that described clamping structure is along described
The circumference of support bar is uniformly distributed.
Nasal sinuses support the most according to claim 1, it is characterised in that described nasal sinuses support is by dropping
Solution macromolecular material is constituted.
8. an induction system, it is characterised in that this induction system includes connecting rod and push rod, wherein,
Described connecting rod is connected to according on the nasal sinuses support described in any one in claim 1-7, and pushing rod sleeve
It is located in described connecting rod.
Induction system the most according to claim 1, it is characterised in that described connecting rod is straight tube-like
Structure, has identical diameter with described support bar.
Induction system the most according to claim 1, it is characterised in that described push rod is that two ends open
The circular tube structure opened, the internal diameter of described push rod is more than the external diameter of described connecting rod, and the external diameter of described push rod is little
Internal diameter in described sleeve pipe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208438.3A CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208438.3A CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106137482A true CN106137482A (en) | 2016-11-23 |
| CN106137482B CN106137482B (en) | 2018-06-29 |
Family
ID=57346590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510208438.3A Active CN106137482B (en) | 2015-04-27 | 2015-04-27 | A kind of nasal sinus stent and transport system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106137482B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913952A (en) * | 2017-02-21 | 2017-07-04 | 东华大学 | A kind of single thread medical multifunctional nasal obstruction and preparation method thereof |
| CN107440762A (en) * | 2017-07-27 | 2017-12-08 | 北京大学第三医院 | Nasal cavity support and its manufacture method |
| CN107693176A (en) * | 2017-09-29 | 2018-02-16 | 翎秀生物科技（上海）有限公司 | The intranasal support of balloon-expandable |
| CN107714243A (en) * | 2017-09-29 | 2018-02-23 | 翎秀生物科技（上海）有限公司 | The intranasal support of self-expansion type |
| CN107753162A (en) * | 2017-09-29 | 2018-03-06 | 翎秀生物科技（上海）有限公司 | The intranasal rack assembly of self-expansion type |
| CN109106483A (en) * | 2018-07-18 | 2019-01-01 | 浦易（上海）生物技术有限公司 | A kind of nasal sinus bracket |
| CN109199655A (en) * | 2018-08-28 | 2019-01-15 | 杨海弟 | It is a kind of hemostasis and medicament slow release art in nasal sinus bracket |
| CN109758278A (en) * | 2019-01-27 | 2019-05-17 | 乐畅医疗器械(上海)有限公司 | A kind of self-expanding nasal sinus bracket and its fetching device |
| CN117137700A (en) * | 2023-10-30 | 2023-12-01 | 江苏启灏医疗科技有限公司 | Nasal sinus support and conveying system |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059193A (en) * | 1989-11-20 | 1991-10-22 | Spine-Tech, Inc. | Expandable spinal implant and surgical method |
| CN1729029A (en) * | 2002-09-18 | 2006-02-01 | 迅息Pty有限公司 | Nasal cavity dilator |
| US7803150B2 (en) * | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
| CN104398328A (en) * | 2014-09-30 | 2015-03-11 | 浦易（上海）生物技术有限公司 | Completely-depredated medicine carrying nasolacrimal stent and implantation system thereof |
| US8998986B1 (en) * | 2013-07-05 | 2015-04-07 | Zdzislaw B. Malinowski | Nasal stent |
| CN204766053U (en) * | 2015-04-27 | 2015-11-18 | 浦易（上海）生物技术有限公司 | Nasal sinus support and conveying system |
-
2015
- 2015-04-27 CN CN201510208438.3A patent/CN106137482B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059193A (en) * | 1989-11-20 | 1991-10-22 | Spine-Tech, Inc. | Expandable spinal implant and surgical method |
| CN1729029A (en) * | 2002-09-18 | 2006-02-01 | 迅息Pty有限公司 | Nasal cavity dilator |
| US7803150B2 (en) * | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
| US8998986B1 (en) * | 2013-07-05 | 2015-04-07 | Zdzislaw B. Malinowski | Nasal stent |
| CN104398328A (en) * | 2014-09-30 | 2015-03-11 | 浦易（上海）生物技术有限公司 | Completely-depredated medicine carrying nasolacrimal stent and implantation system thereof |
| CN204766053U (en) * | 2015-04-27 | 2015-11-18 | 浦易（上海）生物技术有限公司 | Nasal sinus support and conveying system |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913952A (en) * | 2017-02-21 | 2017-07-04 | 东华大学 | A kind of single thread medical multifunctional nasal obstruction and preparation method thereof |
| CN107440762A (en) * | 2017-07-27 | 2017-12-08 | 北京大学第三医院 | Nasal cavity support and its manufacture method |
| CN107440762B (en) * | 2017-07-27 | 2018-08-31 | 北京大学第三医院 | Nasal cavity holder and its manufacturing method |
| CN107693176A (en) * | 2017-09-29 | 2018-02-16 | 翎秀生物科技（上海）有限公司 | The intranasal support of balloon-expandable |
| CN107714243A (en) * | 2017-09-29 | 2018-02-23 | 翎秀生物科技（上海）有限公司 | The intranasal support of self-expansion type |
| CN107753162A (en) * | 2017-09-29 | 2018-03-06 | 翎秀生物科技（上海）有限公司 | The intranasal rack assembly of self-expansion type |
| CN107753162B (en) * | 2017-09-29 | 2020-05-01 | 依奈德医疗技术（上海）有限公司 | Self-expanding intra-nasal stent assembly |
| CN109106483A (en) * | 2018-07-18 | 2019-01-01 | 浦易（上海）生物技术有限公司 | A kind of nasal sinus bracket |
| CN109199655A (en) * | 2018-08-28 | 2019-01-15 | 杨海弟 | It is a kind of hemostasis and medicament slow release art in nasal sinus bracket |
| CN109758278A (en) * | 2019-01-27 | 2019-05-17 | 乐畅医疗器械(上海)有限公司 | A kind of self-expanding nasal sinus bracket and its fetching device |
| CN117137700A (en) * | 2023-10-30 | 2023-12-01 | 江苏启灏医疗科技有限公司 | Nasal sinus support and conveying system |
| CN117137700B (en) * | 2023-10-30 | 2023-12-29 | 江苏启灏医疗科技有限公司 | Nasal sinus support and conveying system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106137482B (en) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106137482B (en) | A kind of nasal sinus stent and transport system | |
| CN102988122B (en) | Prosthetic system for treating nasosinusitis or allergic rhinitis | |
| US10159768B2 (en) | Multi-layer biodegradable device having adjustable drug release profile | |
| CN107427668B (en) | Drug coated balloon | |
| US8740839B2 (en) | Device and methods for treating paranasal sinus conditions | |
| EP2754463B1 (en) | Expandable devices | |
| US11672959B2 (en) | Expandable member systems and methods for drug delivery | |
| CN102988299B (en) | Formation method of drug coating and drug coating prepared by same | |
| CN204766053U (en) | Nasal sinus support and conveying system | |
| CN106344232A (en) | Sustained release medicine bracket for nasal cavity, forming method and application thereof | |
| JP2024060025A (en) | Expandable member systems and methods for drug delivery - Patents.com | |
| CN110141559A (en) | It is a kind of for the pastille slow-release particle of schneiderian membrane and its application | |
| EP3897806A1 (en) | Systems and methods for forming a customized therapeutic support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Puyi (Shanghai) Biotechnology Co.,Ltd. Address before: 201203 room 218, innovation park of traditional Chinese medicine, No. 199, GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee before: PUYI (SHANGHAI) BIOTECHNOLOGY Co.,Ltd. |